Oncolytics Biotech Inc (ONCY) Stock Price, Quote & News

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored...

Industry: Biotechnology

Sector: Healthcare

Phone: 403 670 7377

Fax: 403 283 0858

Website: oncolyticsbiotech.com

Address:

4350 Executive Drive, Suite 325, San Diego, United States

saxy4u Jul. 14 at 6:41 PM

$ONCY here a thought of the D meeting adding the Part B of the registration trial. What if the AIO data is mature and they have seen that adding in Tecentriq gave an advantage and they wanted to add it to the CRC trial and upon agreement with the FDA, they will have a partner for all 3 trials or buyout?

2 · Reply

GammaRadiated Jul. 14 at 5:13 PM

$ONCY grabbed some more after the news - I look it at two more checks marks Jared has completed in the processing of ONCY being acquired

1 · Reply

MariaLollara Jul. 14 at 4:47 PM

$ONCY Why Oncolytics Biotech's FDA Milestone Means More Than Regulatory Progress https://bizfortune.com/2026/07/why-oncolytics-biotech-fda-milestone-matters $CLSK $CRWD $TSM

0 · Reply

RosaEricksona Jul. 14 at 3:27 PM

$ONCY Why Oncolytics Biotech's FDA Milestone Means More Than Regulatory Progress https://bizfortune.com/2026/07/why-oncolytics-biotech-fda-milestone-matters $IBM $CLSK $SKYH

0 · Reply

aaron03 Jul. 14 at 12:53 PM

$ONCY Yesterday's news was outstanding. Unfortunately, it was on a bad day in the market. Hopefully, we have a better day and the market can appreciate the news that ONCY delivered yesterday. I was impressed with the volume. Maybe Kelly can take us to the finish line. Fingers crossed

1 · Reply

Joe0126 Jul. 13 at 11:45 PM

$ONCY glad my order didnt fill at 1.02. terrible day to release news. But im optimistic still.

1 · Reply

Jboogy1st Jul. 13 at 11:42 PM

$ONCY one day we'll win and fly high

0 · Reply

FoxM07 Jul. 13 at 7:41 PM

$ONCY ahh, the exposed paid pumper is back to spread conjecture and nonsense. No BP will even begin to be interested before outstanding interim results come in '27...if they ever do. The "method of use" patent also needs to be extended.

1 · Reply

Notable_Ex Jul. 13 at 7:08 PM

$ONCY By delivering a trial that is actively enrolling with infrastructure ready to scale seamlessly into Part B, ONCY has created a highly attractive, "plug-and-play" asset that a major pharmaceutical company can easily absorb into their existing oncology portfolio

0 · Reply

Notable_Ex Jul. 13 at 6:59 PM

$ONCY By locking in a Type D meeting explicitly focused on a "registrational design," ONCY has radically de-risked its MSS CRC clinical pathway and actively demonstrated company operational momentum while removing any ambiguity on ROI for a Big Pharma suitor, and consequentially incentivizing them to move aggressively.

0 · Reply

Oncolytics provides clinical, regulatory update on REO 033

Jul 13, 2026, 9:00 AM EDT - 1 day ago

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

2026-06-16T13:38:20.000Z - 4 weeks ago

Oncolytics secures new patent for pelareorep manufacturing

Jun 16, 2026, 9:00 AM EDT - 4 weeks ago

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Jun 4, 2026, 12:50 PM EDT - 5 weeks ago

Oncolytics Biotech Transcript: Jefferies Global Healthcare Conference 2026

2026-06-02T14:21:34.000Z - 6 weeks ago

Oncolytics promotes John McAdory to COO

CGON

Jun 2, 2026, 9:00 AM EDT - 6 weeks ago

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

2026-06-01T13:47:40.000Z - 6 weeks ago

Oncolytics announces initial data from pelareorep combination study

Jun 1, 2026, 9:00 AM EDT - 6 weeks ago

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Jun 1, 2026, 7:00 AM EDT - 6 weeks ago

Oncolytics Biotech Slides: Investor presentation

2026-05-22T13:45:50.000Z - 7 weeks ago

Oncolytics Biotech to present data at ASCO 2026 on pelareorep

May 22, 2026, 9:00 AM EDT - 7 weeks ago

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors

May 14, 2026, 4:00 PM EDT - 2 months ago

Oncolytics Biotech Quarterly report: Q1 2026

May 4, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

2026-04-27T13:19:05.000Z - 2 months ago

Oncolytics says in alignment with FDA following pelareorep Type C meeting

Apr 27, 2026, 8:10 AM EDT - 2 months ago

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Oncolytics Biotech Slides: Investor presentation

2026-04-07T14:24:37.000Z - 3 months ago

Oncolytics price target lowered to $5 from $7 at Lake Street

2026-04-06T13:56:11.000Z - 3 months ago

Oncolytics schedules FDA meeting for pelareorep registrational path

Apr 6, 2026, 9:00 AM EDT - 3 months ago

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

2026-04-01T13:39:37.000Z - 3 months ago

Oncolytics completes domicile change to the U.S.

Apr 1, 2026, 9:00 AM EDT - 3 months ago

Oncolytics Biotech® Completes Domicile Change to the United States

Apr 1, 2026, 8:00 AM EDT - 3 months ago

Oncolytics Biotech Registration statement: Registration filing

2026-04-01T10:11:38.000Z - 3 months ago

Oncolytics files $250M mixed securities shelf

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Oncolytics Biotech Annual report: Q4 2025

2026-03-19T13:16:47.000Z - 4 months ago

Oncolytics to present new data on Pelareorep at AACR 2026

Mar 19, 2026, 9:00 AM EDT - 4 months ago

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Mar 3, 2026, 6:00 AM EST - 4 months ago

Oncolytics Biotech Slides: Corporate presentation

2026-03-02T14:12:44.000Z - 4 months ago

Oncolytics initiates randomized colorectal cancer study

Mar 2, 2026, 9:00 AM EST - 4 months ago

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

2026-02-24T14:05:55.000Z - 5 months ago

Oncolytics concludes enrollment in GOBLET study

Feb 24, 2026, 9:00 AM EST - 5 months ago

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

2026-02-04T13:55:27.000Z - 5 months ago

Oncolytics receives FDA Fast Track Designation for pelareorep

Feb 4, 2026, 8:50 AM EST - 5 months ago

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Jan 15, 2026, 4:01 PM EST - 6 months ago

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Jan 15, 2026, 10:00 AM EST - 6 months ago

Oncolytics Biotech Transcript: AGM 2026

2026-01-14T14:15:39.000Z - 6 months ago

Oncolytics appoints John McAdory as EVP, strategy and operations

CGON

Jan 14, 2026, 7:00 AM EST - 6 months ago

Oncolytics Biotech Slides: Investor presentation

2026-01-12T14:10:53.000Z - 6 months ago

Oncolytics announces updates data from GOBLET cohort 4

Jan 12, 2026, 9:00 AM EST - 6 months ago

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

2026-01-09T14:05:19.000Z - 6 months ago

Oncolytics outlines strategic rationale for proposal to change jurisdiction

Jan 9, 2026, 9:00 AM EST - 6 months ago

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Jan 8, 2026, 9:00 AM EST - 6 months ago

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Jan 7, 2026, 9:00 AM EST - 6 months ago

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

2025-12-16T14:20:43.000Z - 7 months ago

Oncolytics reports clinical, translational findings from pelareorep development

Dec 16, 2025, 9:00 AM EST - 7 months ago

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Dec 9, 2025, 6:00 PM EST - 7 months ago

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Nov 20, 2025, 4:05 PM EST - 8 months ago

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

2025-11-19T14:10:13.000Z - 8 months ago

Oncolytics aligns with FDA on pelareorep study design

Nov 19, 2025, 9:00 AM EST - 8 months ago

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Nov 11, 2025, 6:00 PM EST - 8 months ago

Oncolytics Biotech Earnings release: Q3 2025

Oct 28, 2025, 7:30 AM EDT - 9 months ago

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oct 20, 2025, 9:00 AM EDT - 9 months ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Sep 29, 2025, 8:30 AM EDT - 10 months ago

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Sep 16, 2025, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Sep 8, 2025, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Sep 2, 2025, 9:10 AM EDT - 11 months ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Aug 28, 2025, 8:30 AM EDT - 11 months ago

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Aug 22, 2025, 8:00 AM EDT - 11 months ago

Oncolytics Biotech Registration statement: Registration Filing

Aug 11, 2025, 4:55 PM EDT - 1 year ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 8, 2025, 10:00 AM EDT - 1 year ago

Oncolytics Biotech Transcript: AGM 2025

Aug 8, 2025, 10:00 AM EDT - 1 year ago

Oncolytics Biotech Earnings release: Q2 2025

Aug 8, 2025, 9:05 AM EDT - 1 year ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 23, 2025, 9:39 AM EDT - 1 year ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 22, 2025, 3:32 PM EDT - 1 year ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 22, 2025, 1:00 PM EDT - 1 year ago

Oncolytics Biotech Transcript: Status Update

Jul 16, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 10, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

May 23, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings release: Q1 2025

May 14, 2025, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 6, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 10, 2025, 6:09 PM EDT - 1 year ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Annual report: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings release: Q4 2024

Mar 7, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

saxy4u Jul. 14 at 6:41 PM

2 · Reply

GammaRadiated Jul. 14 at 5:13 PM

$ONCY grabbed some more after the news - I look it at two more checks marks Jared has completed in the processing of ONCY being acquired

1 · Reply

MariaLollara Jul. 14 at 4:47 PM

$ONCY Why Oncolytics Biotech's FDA Milestone Means More Than Regulatory Progress https://bizfortune.com/2026/07/why-oncolytics-biotech-fda-milestone-matters $CLSK $CRWD $TSM

0 · Reply

RosaEricksona Jul. 14 at 3:27 PM

$ONCY Why Oncolytics Biotech's FDA Milestone Means More Than Regulatory Progress https://bizfortune.com/2026/07/why-oncolytics-biotech-fda-milestone-matters $IBM $CLSK $SKYH

0 · Reply

aaron03 Jul. 14 at 12:53 PM

1 · Reply

Joe0126 Jul. 13 at 11:45 PM

$ONCY glad my order didnt fill at 1.02. terrible day to release news. But im optimistic still.

1 · Reply

Jboogy1st Jul. 13 at 11:42 PM

$ONCY one day we'll win and fly high

0 · Reply

FoxM07 Jul. 13 at 7:41 PM

1 · Reply

Notable_Ex Jul. 13 at 7:08 PM

0 · Reply

Notable_Ex Jul. 13 at 6:59 PM

0 · Reply

saxy4u Jul. 13 at 5:47 PM

$ONCY I think that we will have a collaboration announcement for the Colorectal Trial and 5 Mill of the shares today will be in exchange for the trial to be expenses by that party whom received those shares In exchange first right at end of data set. IMO

4 · Reply

CaseyLe Jul. 13 at 5:03 PM

$ONCY 7.1 million in volume 😂

0 · Reply

SilverWS Jul. 13 at 4:41 PM

$ONCY WTF? From +16 to Red??

1 · Reply

mosh123 Jul. 13 at 4:30 PM

$ONCY why can`t this one hold the 1 dollar ??

1 · Reply

Arrankar2099 Jul. 13 at 4:24 PM

$ONCY

0 · Reply

focafoca99 Jul. 13 at 2:54 PM

$ONCY preparing a Type D FDA meeting to discuss REO 033 study updates and registrational expansion plans.

1 · Reply

BioRich Jul. 13 at 2:42 PM

$ONCY Moving nicely this morning. Seeing a few new faces after the 20% pop. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more( money. Cheers!

0 · Reply

Volatility_Viking Jul. 13 at 2:40 PM

$ONCY Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

0 · Reply

topstockalerts Jul. 13 at 2:17 PM

$ONCY this one seems determined to prove a point.

0 · Reply

STONESTEELdesign Jul. 13 at 2:16 PM

$ONCY SHE’S IN LABOR NOW 🤓‼️‼️‼️ KEEP ON PUSHING ‼️‼️🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀💎💎💎💎💎💎💎💎 LETS GOOOO MFs‼️‼️‼️‼️

0 · Reply

notreload_ai Jul. 13 at 2:03 PM

$ONCY reports rapid progress in REO 033 trial with pelareorep in RAS-mutant MSS metastatic colorectal cancer. New sites opening, patients enrolling, and FDA Type D meeting planned for August 2026. https://notreload.xyz/xy/oncy-accelerates-reo-033-pelareorep-trial-in-colorectal-cancer/

0 · Reply

exwallstcfo Jul. 13 at 1:49 PM

$ONCY has lots of credibility with FDA ..... that one elusive headline to get us to the promised land just got another step closer

1 · Reply

Market Cap	105.90M
Revenue (ttm)	0.00
Net Income (ttm)	-28.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,896,812
Avg Vol	1,433,912
Day's Range	N/A - N/A
Shares Out	119.35M
Stochastic %K	48%
Beta	1.09
Analysts	Strong Sell
Price Target	$4.87